---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009750"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:41:20.560920+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies

## Summary
- Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.
- Phase 1/1b BP1001-A advanced to dose level 2; expects dose level 3 by year-end.
- Phase 1/1b BP1002 completed second dose cohort (40 mg/m2); advancing to dose level 3 in Q4 2024.
- Developed molecular biomarkers for prexigebersen; preparing preclinical obesity studies.
- Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort; results expected year-end.

## SEC filing metadata
- accession: 0001558370-24-009750
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/0001558370-24-009750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/bpth-20240708x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009750
- JSON: https://secwatch.observer/filing/0001558370-24-009750.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.